Shilpa Medicare Limited (SHILPAMED) AI Stock Analysis

• Market Cap: ₹78.75B
• Dividend Yield: 0.16%
• Average Volume (3M): 38.83K
• Price to Earnings (P/E): 35.2
• Beta (1Y): 0.91
• Revenue Growth: 10.46%
• EPS Growth: 111.15%
• Country: IN
• Employees: 1,007
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.28
• Shares Outstanding: 195,581,820
• 10 Day Avg. Volume: 85,780
• 30 Day Avg. Volume: 38,829
• PEG Ratio: 0.69
• Price to Book (P/B): 2.70
• Price to Sales (P/S): 4.98
• P/FCF Ratio: -57.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 22.1
• Revenue Forecast (FY): ₹17.05B

• Rating: 54 Neutral
• Price Target: ₹318.00 ▼(-0.59% Downside)
• Action: Reiterated Date: 10/23/25
• Date: Action: Reiterated 10/23/25

The overall stock score of 54 reflects a combination of solid financial performance with strong revenue growth and gross margins, but challenges in operational efficiency and liquidity. The technical analysis indicates a bearish trend, and the high P/E ratio suggests potential overvaluation. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Oncology & complex therapies focus

Shilpa's strategic focus on oncology and complex/specialty therapies creates durable barriers: regulatory expertise, specialized manufacturing, and higher-value contracts. This orientation supports sustained pricing power, repeat institutional customers, and long product lifecycles across regulated markets.

Negative Factors

Deteriorating EBIT margin

A near-halving of EBIT margin signals persistent operational efficiency or cost-structure issues that erode profits despite high gross margins. If structural, this reduces operating leverage, limits reinvestment capacity, and weakens the firm's ability to convert sales into durable operating earnings over months.

Shilpa Medicare Limited Business Overview & Revenue Model

Company Description

Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncolo...

Read more

Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncolo...

How the Company Makes Money

Shilpa Medicare makes money primarily by developing, manufacturing, and supplying pharmaceutical products and services across a few core revenue streams: (1) Sale of APIs: The company manufactures and sells APIs, particularly for oncology and othe...

Read more

Shilpa Medicare makes money primarily by developing, manufacturing, and supplying pharmaceutical products and services across a few core revenue streams: (1) Sale of APIs: The company manufactures and sells APIs, particularly for oncology and othe...

Shilpa Medicare Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	13.42B	12.86B	11.53B	10.43B	11.40B	9.00B
Gross Profit	9.61B	8.76B	7.10B	1.34B	7.56B	6.29B
EBITDA	3.48B	3.11B	2.46B	1.13B	2.23B	2.73B
Net Income	1.37B	782.93M	318.74M	-325.33M	606.62M	1.48B
Balance Sheet
Total Assets	34.95B	33.11B	30.93B	29.04B	28.75B	26.32B
Cash, Cash Equivalents and Short-Term Investments	535.50M	585.61M	302.26M	221.92M	338.29M	1.23B
Total Debt	5.93B	5.88B	9.37B	7.98B	6.83B	8.46B
Total Liabilities	10.57B	9.47B	12.93B	11.30B	10.64B	11.65B
Stockholders Equity	24.37B	23.72B	18.09B	17.83B	18.22B	14.79B
Cash Flow
Free Cash Flow	384.68M	-1.11B	-492.22M	-467.44M	-2.27B	-3.07B
Operating Cash Flow	2.01B	1.32B	1.35B	1.80B	1.05B	469.28M
Investing Cash Flow	-1.71B	-1.99B	-1.67B	-2.33B	-2.85B	-4.04B
Financing Cash Flow	-302.20M	626.54M	467.75M	457.98M	828.58M	4.36B

Shilpa Medicare Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 319.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SHILPAMED, the sentiment is Positive. The current price of 319.9 is below the 20-day moving average (MA) of 344.83, below the 50-day MA of 326.18, and below the 200-day MA of 371.12, indicating a bullish trend. The MACD of 18.27 indicates Negative momentum. The RSI at 75.35 is Negative, neither overbought nor oversold. The STOCH value of 94.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SHILPAMED.

Shilpa Medicare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKEM	72 Outperform	₹627.33B	25.97	―	0.80%	9.32%	11.25%
SANOFI	71 Outperform	₹78.80B	38.14	―	4.73%	-19.94%	-22.49%
DRREDDY	70 Outperform	₹993.96B	21.88	―	0.63%	14.10%	9.72%
GLAXO	63 Neutral	₹398.91B	35.44	―	2.16%	4.17%	41.51%
SHILPAMED	54 Neutral	₹78.75B	35.22	―	0.16%	10.46%	111.15%
GLENMARK	53 Neutral	₹613.60B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Shilpa Medicare Limited Corporate Events